| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
The third generation oncolytic herpes simplex virus type 1 G47Δ has artificial triple mutations and exhibits augmented viral replication in tumor cells, enhanced induction of systemic antitumor immunity and high safety features in normal tissues. In this study, we evaluated the therapeutic efficacy of T-hTERT, which regulate ICP6 with hTERT promotor and replicate without dependence on ribonucleotide reductase in host cells to meningioma experimental models. T-hTERT increased more than tenfold replication-competence than T-01, a control virus. In addition, T-hTERT showed excellent cytotoxicity on meningioma models. The results suggest that oncolytic virus therapy will be the new therapeutic strategy for patients with meningiomas.
|
